Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics' Amphotericin B Inhalation Powder has been granted orphan medicinal product designation by the European Commission for the prevention of pulmonary fungal infections in patients deemed at risk.
Subscribe to our email newsletter
Orphan medicinal products are for diagnosing, preventing or treating life-threatening or very serious conditions that are rare and affect less than five of every 10,000 persons in the EU. An orphan drug designation provides 10 years of potential market exclusivity, assistance in preparing the marketing application and assistance for clinical development.
“We are pleased to make continued progress in our Amphotericin B Inhalation Powder (ABIP) program and look forward to using the scientific guidance and assistance available through the EMEA’s Orphan Medicinal Drug Program,” said David Johnston, Nektar senior vice president of research and development.
ABIP is under development for the prevention of pulmonary fungal infections such as aspergillosis in high-risk immunosuppressed patients. Immunosuppressed patients are vulnerable to opportunistic fungal infections, such as aspergillosis, which start in the lungs and spread throughout the body.